Inventor · disambiguated record
Dimitris Skokos
Also filed as: SKOKOS DIMITRIS
14 granted patents·7 pending applications·108 citations·filing 2011–2025
92Inventor score
Top patents by PatentIndex Score
21 records- 0194US11548947B2Bispecific anti-PSMA X anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jan 10, 2023·10 cites·17 claims
- 0294US11414494B2Anti-GITR antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Aug 16, 2022·3 cites·26 claims
- 0394US9556277B2Method of treating a TL1A-associated disease or disorder with human antibodies to TL1AREGENERON PHARMA·Filed 2013·Granted Jan 31, 2017·25 cites·7 claims
- 0493US11453721B2Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Sep 27, 2022·10 cites·30 claims
- 0592US8642741B2Human antibodies to human TNF-like ligand 1A (TL1A)CLASSON BRENDAN J·Filed 2011·Granted Feb 4, 2014·24 cites·13 claims
- 0691US11787867B2Anti-GITR antibodies and uses thereofREGENERON PHARMA·Filed 2021·Granted Oct 17, 2023·2 cites·24 claims
- 0791US11396544B2Bispecific anti-CD28 × anti-CD22 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 26, 2022·8 cites·10 claims
- 0890US10738126B2Anti-GITR antibodies and uses thereofREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·4 cites·4 claims
- 0988US8765125B2Methods of treating autoimmune diseases with Dll4 antagonistsSKOKOS DIMITRIS·Filed 2011·Granted Jul 1, 2014·12 cites·13 claims
- 1085US8889133B2Methods of treating diabetes with Dll4 antagonistsSKOKOS DIMITRIS·Filed 2011·Granted Nov 18, 2014·9 cites·6 claims
- 1183US11912767B2EGFR × CD28 multispecific antibodiesREGENERON PHARMA·Filed 2020·Granted Feb 27, 2024·1 cites·16 claims
- 1277US12331127B2Therapeutic uses of anti-GITR antibodiesREGENERON PHARMA·Filed 2023·Granted Jun 17, 2025·0 cites·55 claims
- 1375US12441800B2Bispecific anti-PSMA x anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Granted Oct 14, 2025·0 cites·14 claims
- 1475US12415856B2EGFR x CD28 multispecific antibodiesREGENERON PHARMA·Filed 2023·Granted Sep 16, 2025·0 cites·10 claims
- 1573US2023042324A1Anti-gitr antibodies and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1671US2023174652A1Bispecific Anti-CD28 X Anti-CD22 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1768US2025223360A1Bispecific anti-cd28 x anti-cd22 antibodies and uses thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1868US2023279113A1Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1961US2023357446A1Compositions and methods for universal tumor cell killingREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2057US2014255429A1Methods of Treating Autoimmune Diseases with DLL4 AntagonistsREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 2151US2017096491A1Human antibodies to human tnf-like ligand 1a (tl1a)REGENERON PHARMA·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →